59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
8 citations
,
September 2023 in “Advanced Pharmaceutical Bulletin” Chitosan-coated spironolactone nano carriers effectively treat acne without side effects.
January 2022 in “International review of movement disorders” Cannabinoid and steroid-based drugs could be new treatments for Tourette syndrome, but more research is needed to confirm their effectiveness and safety.
21 citations
,
April 2016 in “International Journal of Oncology” GnRH treatment can reduce breast cancer cell invasion.
19 citations
,
September 2006 in “Journal of Neurophysiology” Neurosteroids help balance brain signals when certain inhibitions are reduced.
18 citations
,
January 2001 in “Annual Reports in Medicinal Chemistry” Selective Androgen Receptor Modulators (SARMs) are drugs that can control the effects of androgens in different tissues, potentially having fewer side effects and promising for treating various conditions.
May 2025 in “Neuropharmacology” Finasteride reduced seizures and prevented cognitive issues in rats after neonatal asphyxia but increased anxiety later.
25 citations
,
June 2019 in “Endocrine Related Cancer” Mutations in certain receptors can cause diseases and offer new treatment options.
May 2026 in “Reactions Weekly” Finasteride and dutasteride may increase the risk of suicide and sexual dysfunction.
June 2026 in “The Pharmacogenomics Journal”
1 citations
,
February 2008 in “Nature Clinical Practice Urology” Finasteride's sexual side effects may be due to nocebo effect.
165 citations
,
February 1994 in “Fertility and Sterility” Flutamide is more effective and has fewer side effects than spironolactone for treating hirsutism.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
19 citations
,
October 2019 in “Clinical and Experimental Dermatology” Spironolactone reduces pain and lesions in hidradenitis suppurativa patients.
6 citations
,
March 2015 in “Journal of Endocrinological Investigation” Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.
May 2024 in “Aktualʹnì problemi sučasnoï medicini: Vìsnik Ukraïnsʹkoï medičnoï stomatologìčnoï akademì” Spironolactone and clascoterone are promising acne treatments with fewer side effects.
These medications for BPH have known risks and may have new side effects.
3 citations
,
August 2021 in “Uro” Saw palmetto may improve urinary symptoms with fewer sexual side effects compared to some medications.
5 citations
,
October 2014 in “Gynecological Endocrinology” Triptorelin helps evaluate hormone production in Sertoli-Leydig cell tumors.
69 citations
,
July 2015 in “Pharmacotherapy” Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.
32 citations
,
August 1985 in “Clinical endocrinology” Spironolactone may help reduce hair growth and testosterone levels in some women with hirsutism.
April 2021 in “Journal of Investigative Dermatology” Spironolactone safely and effectively treats hair loss in female scarring alopecia patients.
2 citations
,
July 2019 in “Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)” No proven link between isotretinoin and depression.
October 2021 in “International Journal of Andrology” Finasteride, a hair loss drug, has unaddressed sexual side effects due to the manufacturer's inadequate safety measures and lack of additional studies.
December 2013 in “The Journal of Urology” July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” GnRH agonist effectively diagnoses and treats postmenopausal hyperandrogenism from ovarian sources.
2 citations
,
January 2017 in “Annals of Dermatology” Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.
123 citations
,
December 2015 in “Journal of Neuroendocrinology” New targets for making and using brain-synthesized steroids could lead to better treatments for brain disorders and alcoholism.
January 2022 in “Current Enzyme Inhibition” New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.